|1.||Taani, D Q: 2 articles (04/2003 - 12/2001)|
|2.||Chu, Kevin: 1 article (02/2015)|
|3.||Feuer, Nicholas: 1 article (02/2015)|
|4.||Phillips, John: 1 article (02/2015)|
|5.||Choudhury, Muhammad: 1 article (02/2015)|
|6.||Konno, Sensuke: 1 article (02/2015)|
|7.||Rezende, Maria Lúcia Rubo de: 1 article (03/2012)|
|8.||Greghi, Sebastião Luiz Aguiar: 1 article (03/2012)|
|9.||Domingues, Roberta Santos: 1 article (03/2012)|
|10.||Sant'Ana, Adriana Campos Passanezi: 1 article (03/2012)|
12/01/1990 - "In summary, we have demonstrated the production of PL-I by a transplantable rat choriocarcinoma (Rcho). "
03/01/1997 - "This study examined whether the lactogenic hormone negative feedback loop is altered during the ante-partum surge using two models: (i) pregnant rats given a hypothalamic implant of albumin, ovine PRL, or recombinant rat PL-I on Day 19 or 20 of pregnancy; and (ii) pregnant rats bearing a transplant of a rat choriocarcinoma cell line, Rcho-1 (PL-secreting), or HRP-1 (non-PL-secreting). "
01/01/1994 - "To obtain sufficient material for in vitro studies we have used a rPL-I cDNA to express this protein in Chinese hamster ovary (CHO) cells and in these studies have compared the recombinant protein with the native rPL-I. Using an affinity column composed of monoclonal antibody to rPL-I coupled to Sepharose 4B, we have purified rPL-I from four sources: 1) recombinant rPL-I produced and secreted in rPL-I-transfected CHO cells, 2) nonglycosylated recombinant PL-I produced by adding tunicamycin (10 microM/ml medium) to rPL-I-transfected CHO cells, 3) native rPL-I secreted by rat choriocarcinoma (RCHO) cells, and 4) serum rPL-I isolated from day 12 pregnant rats. "
02/01/2015 - "The present study shows that both PL-ES and PL-I-ES indeed have anticancer effects on a variety of cancer cells, although PL-ES appears to be more potent than PL-I-ES. "
02/01/2015 - "PL-I-ES (100 µg/mL) was effective on only four cancer cells but its higher concentration at 250 µg/mL led to a significant (25-90%) growth reduction in seven cancer cells. "
02/01/2015 - "As anticancer effects of similar extracts have been reported in several cancers, we investigated whether PL-ES and PL-I-ES might have such anticancer activities on a variety of human cancer cells in vitro. "
08/01/1996 - "These tumors also secreted PL-I into the circulation, as shown by radioimmunoassay."
02/01/2015 - "Ten different types of human cancer cell lines, including three metastatic prostate, bladder, kidney, lung, breast, stomach, liver, and brain cancer cells, were employed and tested with PL-ES or PL-I-ES. "
03/01/2012 - "Clinical parameters investigated included pocket probing depth (PD), clinical attachment level (CAL), sulcular bleeding index (SBI) and plaque index (Pl.I). "
07/01/1996 - "The Gingival Index (GI), Sulcus Bleeding Index (SBI) and Plaque Index (Pl-I) were individually scored. "
01/01/1995 - "Gingival crevicular fluid (GCF), papilla bleeding index (PBI), plaque index (Pl-I), probing depth (PD), and relative attachment level (AL) were measured. "
03/01/1990 - "Plaque index (Pl I) and bleeding scores increased significantly on banded teeth as compared with control sites. "
01/01/1992 - "20 untreated chronic periodontitis patients were given a full periodontal examination, including measurements of probing depth (PD), clinical attachment loss (CAL), gingival index (GI), bleeding index (BI) and plaque index (Pl.I.). "
|4.||Dental Caries (White Spot)
12/01/2001 - "All participants had dental examinations for oral hygiene, gingival condition and dental caries experience using the Silness and Löe plaque index (Pl.I), Löe and Silness gingival index (GI) and decayed (D), missing (M) and filled (F) teeth (DMFT) and surfaces (DMFS) codes, respectively. "
12/01/2002 - "A total of 61 thalassemia patients and 63 healthy controls (age range = 6-18 years) were examined for plaque deposits, gingivitis, periodontitis and dental caries using Silness and Löe plaque index (Pl.I), Löe and Silness gingival index (GI), probing pocket depth (PPD) and DMFT, respectively. "
|1.||Complementary DNA (cDNA)
|5.||1- myristoyl- 2- (2- azido- 4- nitrobenzoyl)phosphatidylcholine (PL II)
|7.||Messenger RNA (mRNA)
|8.||Conditioned Culture Media
|9.||Staphylococcal Protein A (A, Protein)
|10.||Proteins (Proteins, Gene)
|2.||Oral Hygiene (Dental Hygiene)